Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · IEX Real-Time Price · USD
0.168
-0.018 (-9.92%)
At close: Jul 19, 2024, 4:00 PM
0.170
+0.002 (1.01%)
Pre-market: Jul 22, 2024, 8:59 AM EDT
Allarity Therapeutics Employees
As of December 31, 2023, Allarity Therapeutics had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 3 or -33.33% compared to the previous year.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$3,490,000
Market Cap
4.30M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
OpGen | 100 |
Genetic Technologies | 60 |
Predictive Oncology | 35 |
Genprex | 26 |
Trevena | 23 |
Sonnet BioTherapeutics Holdings | 12 |
CERo Therapeutics Holdings | 9 |
MyMD Pharmaceuticals | 6 |
ALLR News
- 2 hours ago - Allarity Therapeutics Outlines Company's 2024 Progress and Objectives - GlobeNewsWire
- 25 days ago - Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 - GlobeNewsWire
- 2 months ago - Allarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer - GlobeNewsWire
- 3 months ago - Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement - GlobeNewsWire